LYG-202, a Newly Synthesized Flavonoid, Exhibits Potent Anti-angiogenic Activity In Vitro and In Vivo

被引：21

作者：

Chen, Yan ^{[1
]}

Lu, Na ^{[1
]}

Ling, Yun ^{[1
]}

Wang, Ling ^{[1
]}

You, Qidong ^{[1
]}

Li, Zhiyu ^{[1
]}

Guo, Qinglong ^{[1
]}

机构：

[1] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Peoples R China

来源：

JOURNAL OF PHARMACOLOGICAL SCIENCES | 2010年 / 112卷 / 01期

基金：

中国国家自然科学基金;

关键词：

flavonoid; angiogenesis; human umbilical vein endothelial cell (HUVEC); vascular endothelial growth factor (VEGF); KDR/Flk-1 (VEGFR-2); ENDOTHELIAL GROWTH-FACTOR; INDUCED TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; VEGF; INHIBITION; MECHANISMS; KDR/FLK-1; RECEPTOR;

D O I：

10.1254/jphs.09213FP

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

LYG-202 (C25H30N2O5) is a newly synthesized flavonoid that has been confirmed to possess an antitumor effect, but the mechanism is unclear. Our present study was performed to identify the anti-angiogenic activity of this novel compound in vitro and in vivo. LYG-202 inhibited vascular endothelial growth factor (VEGF) Stimulated migration and tube formation of human umbilical vein endothelial cells and arrested microvessel outgrowth from rat aortic rings in vitro. Meanwhile, LYG-202 suppressed the neovascularization of Chicken Chorioallantoic Membrane in vivo. Mechanistic studies revealed that LYG-202 suppressed the VEGF-induced tyrosine phosphorylation of KDR/Flk-1 (VEGFR-2) as well as its downstream protein kinases activation, by decreasing phosphorylated forms of serine/threonine kinase Akt, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase. LYG-202 exerts anti-angiogenic activity both in vitro and in vivo, and these results suggest that it deserves further investigation as a promising anti-tumor angiogenesis compound.

引用

页码：37 / 45

页数：9

共 38 条

[11] Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models [J].